Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction a community-based study

Circulation: Heart Failure

Volumn 5, Issue 6, 2012, Pages 710-719

  Mohammed, Selma F ^a   Borlaug, Barry A ^a   Roger, Véronique L ^a,b   Mirzoyev, Sultan A ^a,c   Rodeheffer, Richard J ^a   Chirinos, Julio A ^a,e   Redfield, Margaret M ^a,d  

^a Mayo Clinic   (United States)

^b Department of Health Sciences Research ^*  (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anemia; Diabetes mellitus; Heart failure with preserved ejection fraction; Hypertension; Obesity; Renal dysfunction

Indexed keywords

AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANEMIA; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART ATRIA; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; OBESITY; STROKE VOLUME;

EID: 84873618584     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.968594     Document Type: Article

References (42)

1. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123:1996-2004; discussion 2005.
2. Packer M. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail. 2011;4:538-540.
3. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: Treat now by treating comorbidities. JAMA. 2008;300:431-433.
4. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
5. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.
6. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
7. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;54:410-418.
8. Chantler PD, Clements RE, Sharp L, George KP, Tan LB, Goldspink DF. The influence of body size on measurements of overall cardiac function. Am J Physiol Heart Circ Physiol. 2005;289:H2059-H2065.
9. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513-521.
10. Chantler PD, Lakatta EG. Role of body size on cardiovascular function: Can we see the meat through the fat? Hypertension. 2009;54:459-461.
11. Chirinos JA, Rietzschel ER, De Buyzere ML, De Bacquer D, Gillebert TC, Gupta AK, Segers P; Asklepios investigators. Arterial load and ventricular-arterial coupling: Physiologic relations with body size and effect of obesity. Hypertension. 2009;54:558-566.
12. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER. Left ventricular mass: Allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension. 2010;56:91-98.
13. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;52:2148-2155.
14. Mitchell GF, Lacourcière Y, Ouellet JP, Izzo JL Jr, Neutel J, Kerwin LJ, Block AJ, Pfeffer MA. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: The role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation. 2003;108:1592-1598.
15. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: A community-based study. J Am Coll Cardiol. 2009;53:1119-1126.
16. López-Jiménez F, Cortés-Bergoderi M. Update: Systemic diseases and the cardiovascular system (i): Obesity and the heart. Rev Esp Cardiol. 2011;64:140-149.
17. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501-511.
18. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485-493.
19. Dhingra R, Vasan RS. Diabetes and the risk of heart failure. Heart Fail Clin. 2012;8:125-133.
20. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010;16:971-979.
21. Pateinakis P, Papagianni A. Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: Epidemiology, pathogenesis, and management. Int J Nephrol. 2011;2011:938651.
22. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: A kidney-heart connection. Am J Physiol Regul Integr Comp Physiol. 2012;302:R292-R299.
23. Mitchell GF, Conlin PR, Dunlap ME, Lacourcière Y, Arnold JM, Ogilvie RI, Neutel J, Izzo JL Jr, Pfeffer MA. Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension. 2008;51:105-111.
24. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part II: The aging heart in health: Links to heart disease. Circulation. 2003;107:346-354.
25. Güder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT, Ertl G, Angermann CE, Störk S. Reverse epidemiology in systolic and nonsystolic heart failure: Cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail. 2009;2:563-571.
26. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: Paradox or reverse epidemiology? Eur Heart J. 2005;26:5-7.
27. Kalantar-Zadeh K, Anker SD, Coats AJ, Horwich TB, Fonarow GC. Obesity paradox as a component of reverse epidemiology in heart failure. Arch Intern Med. 2005;165:1797; author reply 1797-1797; author reply 1798.
28. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324-331.
29. Olivetti G, Quaini F, Lagrasta C, Ricci R, Tiberti G, Capasso JM, Anversa P. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol. 1992;141:227-239.
30. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS. Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol. 1995;25:1402-1407.
31. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-827.
32. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the national health and nutrition examination survey III: Prevalence and associations with anemia and inflammation. Circ Heart Fail. 2011;4:599-606
33. Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail. 2010;16:96-103.
34. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbély A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43-51.
35. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: Findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4:27-35.
36. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377-1385.
37. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med. 2006;119:591-599.
38. Tribouilloy C, Rusinaru D, Mahjoub H, Tartière JM, Kesri-Tartière L, Godard S, Peltier M. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: A prospective five-year study. Heart. 2008;94:1450-1455.
39. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, Bauters C. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25:656-662.
40. Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, Tavazzi L, Maggioni AP; BRING-UP Investigators. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. J Card Fail. 2003;9:192-202.
41. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-1996.
42. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854.